ShareThis Page
FDA cracking down on anti-diarrhea drug Imodium because of opiate side effects |

FDA cracking down on anti-diarrhea drug Imodium because of opiate side effects

Suzanne Elliott
| Wednesday, January 31, 2018 11:45 a.m

In an effort to combat the opioid crisis, The Food and Drug Administration announced plans Tuesday to place restrictions on the packaging of Imodium AD medication sold over the counter.

Imodium AD, used to treat short-term bouts of diarrhea, contains loperamide, a drug with opiate side effects. High doses of the drug can flood the brain’s receptors and produce a feeling of exhilaration akin to other opioids.

The FDA said abuse of loperamide has been increasing and recommended Imodium packaging be limited to “eight 2-milligram capsules in blister packaging.”

Loperamide is sometimes referred to as “poor man’s methadone,” according to a Forbes report .

“When used at extremely high and dangerous doses, it’s seen by those suffering from opioid addiction as a potential alternative to manage opioid withdrawal symptoms or to achieve the euphoric effects of opioid use,” FDA Commissioner Scott Gottlieb said in a statement.

The FDA said it is planning to reach out to online loperamide distributors to ask them to take voluntary steps to address the abuse issue. Also, the FDA said the new packaging should limit sales. More than 11.5 million Americans abused prescription opioids in 2017, with more than 40 people dying every day, the FDA said.

Suzanne Elliott is a Tribune-Review staff writer. Reach her at or via Twitter @41Suzanne.

Categories: Health Now
TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.